AstraZeneca PLC is continuing to go big on antibody drug conjugates (ADCs), paying $1bn upfront for ex-Japan global development and commercialization rights to a second such asset from existing partner Daiichi Sankyo Co., Ltd., in a deal that could be worth up to $6bn in total to the Japanese pharma company including future regulatory and sales milestones.
AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
$1bn Upfront To Secure New Asset
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
